| First Author | Takaso Y | Year | 2020 |
| Journal | Sci Rep | Volume | 10 |
| Issue | 1 | Pages | 17795 |
| PubMed ID | 33082370 | Mgi Jnum | J:298996 |
| Mgi Id | MGI:6472296 | Doi | 10.1038/s41598-020-73984-3 |
| Citation | Takaso Y, et al. (2020) Deletion of CD38 and supplementation of NAD(+) attenuate axon degeneration in a mouse facial nerve axotomy model. Sci Rep 10(1):17795 |
| abstractText | Following facial nerve axotomy, nerve function is not fully restored even after reconstruction. This may be attributed to axon degeneration/neuronal death and sustained neuroinflammation. CD38 is an enzyme that catalyses the hydrolysis of nicotinamide adenine dinucleotide (NAD(+)) and is a candidate molecule for regulating neurodegeneration and neuroinflammation. In this study, we analyzed the effect of CD38 deletion and NAD(+) supplementation on neuronal death and glial activation in the facial nucleus in the brain stem, and on axon degeneration and immune cell infiltration in the distal portion of the facial nerve after axotomy in mice. Compared with wild-type mice, CD38 knockout (KO) mice showed reduced microglial activation in the facial nucleus, whereas the levels of neuronal death were not significantly different. In contrast, the axon degeneration and demyelination were delayed, and macrophage accumulation was reduced in the facial nerve of CD38 KO mice after axotomy. Supplementation of NAD(+) with nicotinamide riboside slowed the axon degeneration and demyelination, although it did not alter the level of macrophage infiltration after axotomy. These results suggest that CD38 deletion and supplementation of NAD(+) may protect transected axon cell-autonomously after facial nerve axotomy. |
